由α2-上腺素受体激活引发的瘤免疫排斥
Jingjing Zhu1,2,3, Stefan Naulaerts4,5, Loubna Boudhan4,5,6
1Ludwig Institute for Cancer Research, Brussels, Belgium. jingjng.zhu@uclouvain.be.
Nature
|June 7, 2023
概括
作为单一疗法,α2-上腺素受体 (α2-AR) 激素具有强大的抗瘤活性,即使在免疫检查点阻断性癌症中也是如此. 这些发现表明α2-AR激动剂可以增强癌症免疫疗法的疗效.
科学领域:
- 免疫学
- 药理学
- 癌症学
背景情况:
- 免疫检查点阻塞 (ICB) 疗法在癌症治疗中表现有前途,但面临阻力.
- 结合ICB与免疫抑制剂的疗效有限.
- 瘤微环境调节对于改善癌症免疫治疗反应至关重要.
研究的目的:
- 研究α2-上腺素受体 (α2-AR) 激动剂的抗瘤潜力.
- 确定α2-AR激动剂在癌症中的作用机制和细胞点.
- 在ICB耐药和免疫能力强的癌症模型中评估α2-AR激动剂的疗效.
主要方法:
- 在免疫能力和免疫缺陷的小鼠瘤模型中测试α2-AR激动剂作为单一疗法.
- 使用人类淋巴细胞进行人体瘤移植.
- 使用α2-AR抗剂和Adra2a敲击小鼠来确认目标效应.
- 进行单细胞RNA测序和免疫细胞分析 (T淋巴细胞,骨髓抑制细胞,巨细胞).
主要成果:
- 在具有免疫能力的模型中,α2-AR激动剂表现出显著的抗瘤活性,包括对ICB耐药的模型,但在免疫缺陷模型中没有.
- 治疗导致T淋巴细胞透的增加,并减少了更多的亡性骨髓抑制细胞.
- 单细胞RNA测序显示巨细胞和T细胞的先天和适应性免疫反应得到增强.
- α2-AR激动剂需要CD4+,CD8+T淋巴细胞和巨细胞才能有效,直接作用于巨细胞以增强T淋巴细胞的刺激.
结论:
- α2-AR激动剂具有强大的本质抗瘤活性,对宿主免疫细胞,特别是巨细胞起作用.
- 这些激动剂可以克服ICB耐药性并增强抗瘤免疫力.
- 临床上可用的α2-AR激动剂是改善癌症免疫治疗结果的有希望的治疗策略.
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Cell-mediated Immune Responses
83.5K
Overview
83.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Sympathetic Signaling
2.2K
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
2.2K


